Compare Sterling Biotech with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs GLENMARK PHARMA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH GLENMARK PHARMA STERLING BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x -0.4 17.5 - View Chart
P/BV x 0.0 2.9 0.5% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 STERLING BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
GLENMARK PHARMA
Mar-19
STERLING BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs11712 1.5%   
Low Rs3484 0.7%   
Sales per share (Unadj.) Rs26.8349.6 7.7%  
Earnings per share (Unadj.) Rs-15.032.8 -45.6%  
Cash flow per share (Unadj.) Rs-5.544.3 -12.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs54.9198.6 27.6%  
Shares outstanding (eoy) m267.87282.17 94.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.7 15.2%   
Avg P/E ratio x-0.518.2 -2.5%  
P/CF ratio (eoy) x-1.313.5 -9.4%  
Price / Book Value ratio x0.13.0 4.2%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m1,862168,625 1.1%   
No. of employees `0001.412.0 11.2%   
Total wages/salary Rs m54720,561 2.7%   
Avg. sales/employee Rs Th5,303.38,196.0 64.7%   
Avg. wages/employee Rs Th403.81,708.1 23.6%   
Avg. net profit/employee Rs Th-2,959.0768.5 -385.1%   
INCOME DATA
Net Sales Rs m7,18198,655 7.3%  
Other income Rs m432,081 2.0%   
Total revenues Rs m7,223100,736 7.2%   
Gross profit Rs m94715,858 6.0%  
Depreciation Rs m2,5433,259 78.0%   
Interest Rs m4,3773,346 130.8%   
Profit before tax Rs m-5,93111,335 -52.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m-1,9243,756 -51.2%   
Profit after tax Rs m-4,0079,250 -43.3%  
Gross profit margin %13.216.1 82.0%  
Effective tax rate %32.433.1 97.9%   
Net profit margin %-55.89.4 -595.1%  
BALANCE SHEET DATA
Current assets Rs m14,33566,968 21.4%   
Current liabilities Rs m49,80940,211 123.9%   
Net working cap to sales %-494.027.1 -1,821.5%  
Current ratio x0.31.7 17.3%  
Inventory Days Days40383 484.1%  
Debtors Days Days17181 210.2%  
Net fixed assets Rs m55,43233,322 166.4%   
Share capital Rs m268282 94.9%   
"Free" reserves Rs m13,93555,770 25.0%   
Net worth Rs m14,70156,052 26.2%   
Long term debt Rs m9,47835,738 26.5%   
Total assets Rs m73,988132,888 55.7%  
Interest coverage x-0.44.4 -8.1%   
Debt to equity ratio x0.60.6 101.1%  
Sales to assets ratio x0.10.7 13.1%   
Return on assets %0.59.5 5.3%  
Return on equity %-27.316.5 -165.1%  
Return on capital %-6.417.8 -36.1%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86062,998 3.0%   
Fx outflow Rs m2522,859 0.1%   
Net fx Rs m1,83540,140 4.6%   
CASH FLOW
From Operations Rs m1,71913,242 13.0%  
From Investments Rs m-3,148-6,990 45.0%  
From Financial Activity Rs m1,426-7,387 -19.3%  
Net Cashflow Rs m-3-2,971 0.1%  

Share Holding

Indian Promoters % 33.9 48.3 70.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 6.9 -  
FIIs % 9.9 34.4 28.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 10.5 374.3%  
Shareholders   21,482 56,727 37.9%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON   

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS